Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling

Blood

Volumn 117, Issue 18, 2011, Pages 4946-4952

  Gao, Cunji ^a   Boylan, Brian ^a   Fang, Juan ^a   Wilcox, David A ^a   Newman, Debra K ^a   Newman, Peter J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FONDAPARINUX; HEPARIN; INTEGRIN; INTEGRIN ALPHAIIBBETA3; PENTASACCHARIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SPREADING; CELL STRUCTURE; DRUG ACTIVITY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION;

EID: 79955964309     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-307751     Document Type: Article

References (52)

1. Arbit E, Goldberg M, Gomez-Orellana I, Majuru S. Oral heparin: status review. Thromb J. 2006;4(6):1-7.
2. Sappington SW. The use of heparin in blood transfusions. JAMA. 1939;113(1):22-25.
3. Eika C. On the mechanism of platelet aggregation induced by heparin, protamine and polybrene. Scand J Haematol. 1972;9(3):248-257.
4. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecularweight heparin and with a direct thrombin inhibitor. Circulation. 1998;97(3):251-256. (Pubitemid 28067310)
5. Rauova L, Zhai L, Kowalska MA, et al. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood. 2006;107(6):2346-2353. (Pubitemid 43345554)
6. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009;113(20):4970-4976.
7. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost. 1995;21(1):106-116.
8. Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res. 1988;50(6):815-826.
9. Horne MK III, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol. 1998; 58(1):24-30. (Pubitemid 28213555)
10. Anand SX, Kim MC, Kamran M, et al. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol. 2007;100(3):417-424. (Pubitemid 47094690)
11. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65(1):64-73. (Pubitemid 10214332)
12. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg. 2001;33(3):587-594. (Pubitemid 32215610)
13. Chong BH, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol. 1989;43(3):245-251. (Pubitemid 19252208)
14. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alpha IIb beta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011-3025.
15. Woulfe DS. Akt signaling in platelets and thrombosis. Expert Rev Hematol. 2010;3(1):81-91.
16. Banfic H, Tang X, Batty IH, et al. A novel integrin-activated pathway forms PKB/Akt-stimulatory phosphatidylinositol 3,4-bisphosphate via phosphatidylinositol 3-phosphate in platelets. J Biol Chem. 1998;273(1):13-16. (Pubitemid 28042167)
17. Yin H, Stojanovic A, Hay N, Du X. The role of Akt in the signaling pathway of the glycoprotein Ib-IX induced platelet activation. Blood. 2008;111(2): 658-665.
18. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003;116(8):1409-1416. (Pubitemid 36527488)
19. Boylan B, Gao C, Rathore V, et al. Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets. Blood. 2008;112(7): 2780-2786.
20. Gao C, Boylan B, Bougie D, et al. Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain. J Clin Invest. 2009; 119(3):504-511.
21. Patil S, Newman DK, Newman PJ. Platelet endothelial cell adhesion molecule-1 serves as an inhibitory receptor that modulates platelet responses to collagen. Blood. 2001;97(6):1727-1732. (Pubitemid 32217240)
22. Cella G, Scattolo N, Luzzatto G, Girolami A. Effects of low-molecular-weight heparin on platelets as compared with commercial heparin. Res Exp Med (Berl). 1984;184(4):227-229. (Pubitemid 14064227)
23. Li D, August S, Woulfe DS. GSK3-beta is a negative regulator of platelet function and thrombosis. Blood. 2008;111(7):3522-3530.
24. Shattil SJ, Haimovich B, Cunningham M, et al. Tyrosine phosphorylation of pp125FAK in platelets requires coordinated signaling through integrin and agonist receptors. J Biol Chem. 1994; 269(20): 14738-14745.
25. Schaller MD, Hildebrand JD, Shannon JD, et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol. 1994;14(3):1680-1688.
26. Hitchcock IS, Fox NE, Prevost N, et al. Roles of focal adhesion kinase (FAK) in megakaryopoiesis and platelet function: studies using a megakaryocyte lineage specific FAK knockout. Blood. 2008; 111(2):596-604.
27. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol. 1997; 11(3):489-509. (Pubitemid 27470554)
28. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008;359(25):2674-2684.
29. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood. 2008;112(7):2607-2616.
30. Poncz M. Mechanistic basis of heparin-induced thrombocytopenia. Semin Thorac Cardiovasc Surg. 2005;17(1):73-79. (Pubitemid 40521334)
31. Saba HI, Saba SR, Blackburn CA, Hartmann RC, Mason RG. Heparin neutralization of PGI2: effects upon platelets. Science. 1979;205(4405): 499-501.
32. Weber DR, Nichols WK, Mohammad SF. Effect of heparin on platelet aggregation inhibited by PGI2, trifluoperazine and verapamil. Thromb Res. 1986; 42(4):477-487. (Pubitemid 16073470)
33. Cooney MF. Heparin-induced thrombocytopenia: advances in diagnosis and treatment. Crit Care Nurse. 2006;26(6):30-36.
34. Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. Lancet. 1982;2(8310):1246-1249.
35. Munoz EM, Linhardt RJ. Heparin-binding domains in vascular biology. Arterioscler Thromb Vasc Biol. 2004;24(9):1549-1557. (Pubitemid 39180876)
36. Fujimura Y, Titani K, Holland LZ, et al. A heparin-binding domain of human von Willebrand factor: characterization and localization to a tryptic fragment extending from amino acid residue Val-449 to Lys-728. J Biol Chem. 1987;262(4):1734-1739.
37. Bentley KL, Klebe RJ, Hurst RE, Horowitz PM. Heparin binding is necessary, but not sufficient, for fibronectin aggregation: a fluorescence polarization study. J Biol Chem. 1985;260(12):7250-7256.
38. Simonis D, Fritzsche J, Alban S, Bendas G. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition. Biochemistry. 2007;46(20):6156-6164. (Pubitemid 46799175)
39. Yu H, Tyrrell D, Cashel J, et al. Specificities of heparin-binding sites from the amino-terminus and type 1 repeats of thrombospondin-1. Arch Biochem Biophys. 2000;374(1):13-23. (Pubitemid 30084403)
40. Edens RE, LeBrun LA, Linhardt RJ, Kaul PR, Weiler JM. Certain high molecular weight heparin chains have high affinity for vitronectin. Arch Biochem Biophys. 2001;391(2):278-285. (Pubitemid 32662270)
41. Denton J, Lane DA, Thunberg L, Slater AM, Lindahl U. Binding of platelet factor 4 to heparin oligosaccharides. Biochem J. 1983;209(2):455-460. (Pubitemid 13163719)
42. de Vet EC, Newland SA, Lyons PA, Aguado B, Campbell RD. The cell surface receptor G6b, a member of the immunoglobulin superfamily, binds heparin. Febs Lett. 2005;579(11):2355-2358. (Pubitemid 40569504)
43. Wijelath ES, Murray J, Rahman S, et al. Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res. 2002; 91(1):25-31. (Pubitemid 34778938)
44. Faye C, Moreau C, Chautard E, et al. Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem. 2009;284(33): 22029-22040.
45. Fitzgerald LA, Leung B, Phillips DR. A method for purifying the platelet membrane glycoprotein IIb-IIIa complex. Anal Biochem. 1985;151(1):169-177. (Pubitemid 16155021)
46. Horne MK III. Heparin binding to normal and abnormal platelets. Thromb Res. 1988;51(2):135-144.
47. Vorup-Jensen T, Carman CV, Shimaoka M, et al. Exposure of acidic residues as a danger signal for recognition of fibrinogen and other macromolecules by integrin alphaXbeta2. Proc Natl Acad Sci USA. 2005;102(5):1614-1619. (Pubitemid 40209216)
48. Vorup-Jensen T, Chi L, Gjelstrup LC, et al. Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. J Biol Chem. 2007;282(42): 30869-30877. (Pubitemid 350035199)
49. Hsu LC. Heparin-coated cardiopulmonary bypass circuits: current status. Perfusion. 2001;16(5): 417-428.
50. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352(9129):673-681. (Pubitemid 28398701)
51. Vrolix MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial): MENTOR Trial Investigators. Am J Cardiol. 2000;86(4):385-389. (Pubitemid 30628602)
52. Haude M, Konorza TF, Kalnins U, et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation. 2003;107(9):1265-1270. (Pubitemid 36314409)